Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. ACN
5. IBM
6. META
7. SPY
8. NVDA
9. PRIM
10. PFE

Go back to Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease

Axsome Therapeutics (AXSM) PT Raised to $302 at RBC Capital

May 4, 2026 4:07 PM EDT

RBC Capital analyst Leonid Timashev raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $302.00 (from $242.00) while maintaining a Outperform rating.

The analyst comments "Today, AXSM reported 1Q26 earnings, and we had a chance to catch up with mgmt. Auvelity in... More